0.06
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SYBLEU
Its shares trade under the ticker SYBE. It has been listed since 9 March 2023. In the fiscal year to 30 June 2023, it reported revenue of $11,700 and a net loss of $180,300. At that date it held total assets of $330,500 and shareholders' equity of −$351,000.
SYBLEU, Inc. intends to engage in the development of regenerative medical applications. The company is headquartered in Bronx, New York. The company went IPO on 2023-03-09. The firm is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The firm is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. The company is also involved in the development of disposable medical devices. The company has completed Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 9 Mar 2023
Leadership
Pay as last reported
- Mr. Jeremy DaveyChairman of the Board, Chief Executive Officer, since 2024
- Mr. Laman MilnerPresident, Director, since 2024
- Mr. John ClarkCompany Secretary, Director, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SYBLEU Inc. completed Phase I and II clinical trials for regenerative medical applications in Bronx, New York.
- The company focuses on therapies for human and animal health with AI-driven clinical diagnostics.
- SYBLEU develops disposable medical devices and cancer drugs for companion animals in the US market.
Weaknesses
- SYBLEU Inc. has not yet advanced to Phase III clinical trials for its regenerative medical applications.
- The company's development stage limits immediate commercialization of its therapies and devices.
- SYBLEU's focus on animal health drugs may face regulatory challenges in the US market.
Opportunities
- SYBLEU can expand its AI and machine learning applications in clinical diagnostics for broader healthcare use.
- The growing market for companion animal cancer treatments offers significant revenue potential in the US.
- Partnerships with US healthcare providers could accelerate the adoption of SYBLEU's disposable medical devices.
Threats
- Regulatory hurdles in the US may delay the approval of SYBLEU's animal health drugs.
- Competition from established US medical device companies could impact SYBLEU's market entry.
- The high costs of Phase III clinical trials pose a financial risk for SYBLEU's development pipeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.